Literature DB >> 28480067

Radiation therapy for hepatobiliary malignancies.

Jonathan W Lischalk1, Michael C Repka1, Keith Unger1.   

Abstract

Hepatobiliary malignancies represent a heterogeneous group of diseases, which often arise in a background of underlying hepatic dysfunction complicating their local management. Surgical resection continues to be the standard of care for hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC); unfortunately the majority of patients are inoperable at presentation. The aggressiveness of these lesions makes locoregional control of particular importance. Historical experience with less sophisticated radiotherapy resulted in underwhelming efficacy and oftentimes prohibitive liver toxicity. However, with the advent of extremely conformal and precise radiotherapy delivery, dose escalation to the tumor with sparing of surrounding normal tissue has yielded notable improvements in efficacy for this modality of treatment. Dose escalation has come in a variety of forms most notably as stereotactic body radiation therapy (SBRT) and hypofractionated proton therapy. As radiation techniques continue to improve, their proper incorporation into the local management of hepatobiliary malignancies will be paramount in improving the prognosis of what is a grave diagnosis.

Entities:  

Keywords:  Hepatobiliary cancer; cholangiocarcinoma (CC); hepatocellular carcinoma (HCC); hypofractionation; proton therapy; stereotactic body radiation therapy (SBRT)

Year:  2017        PMID: 28480067      PMCID: PMC5401861          DOI: 10.21037/jgo.2016.08.02

Source DB:  PubMed          Journal:  J Gastrointest Oncol        ISSN: 2078-6891


  52 in total

1.  Escalated focal liver radiation and concurrent hepatic artery fluorodeoxyuridine for unresectable intrahepatic malignancies.

Authors:  L A Dawson; C J McGinn; D Normolle; R K Ten Haken; S Walker; W Ensminger; T S Lawrence
Journal:  J Clin Oncol       Date:  2000-06       Impact factor: 44.544

2.  Stereotactic body radiation therapy in recurrent hepatocellular carcinoma.

Authors:  Wen-Yen Huang; Yee-Min Jen; Meei-Shyuan Lee; Li-Ping Chang; Chang-Ming Chen; Kai-Hsiung Ko; Kuen-Tze Lin; Jang-Chun Lin; Hsing-Lung Chao; Chun-Shu Lin; Yu-Fu Su; Chao-Yueh Fan; Yao-Wen Chang
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-02-17       Impact factor: 7.038

3.  Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.

Authors:  Juan Valle; Harpreet Wasan; Daniel H Palmer; David Cunningham; Alan Anthoney; Anthony Maraveyas; Srinivasan Madhusudan; Tim Iveson; Sharon Hughes; Stephen P Pereira; Michael Roughton; John Bridgewater
Journal:  N Engl J Med       Date:  2010-04-08       Impact factor: 91.245

4.  Outcomes After Stereotactic Body Radiotherapy or Radiofrequency Ablation for Hepatocellular Carcinoma.

Authors:  Daniel R Wahl; Matthew H Stenmark; Yebin Tao; Erqi L Pollom; Elaine M Caoili; Theodore S Lawrence; Matthew J Schipper; Mary Feng
Journal:  J Clin Oncol       Date:  2015-11-30       Impact factor: 44.544

5.  Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials.

Authors:  Joe Y Chang; Suresh Senan; Marinus A Paul; Reza J Mehran; Alexander V Louie; Peter Balter; Harry J M Groen; Stephen E McRae; Joachim Widder; Lei Feng; Ben E E M van den Borne; Mark F Munsell; Coen Hurkmans; Donald A Berry; Erik van Werkhoven; John J Kresl; Anne-Marie Dingemans; Omar Dawood; Cornelis J A Haasbeek; Larry S Carpenter; Katrien De Jaeger; Ritsuko Komaki; Ben J Slotman; Egbert F Smit; Jack A Roth
Journal:  Lancet Oncol       Date:  2015-05-13       Impact factor: 41.316

6.  Natural History and Prognostic Factors of Advanced Cholangiocarcinoma without Surgery, Chemotherapy, or Radiotherapy: A Large-Scale Observational Study.

Authors:  Jongha Park; Myung-Hwan Kim; Kyu-Pyo Kim; Do Hyun Park; Sung-Hoon Moon; Tae Jun Song; Junbum Eum; Sang Soo Lee; Dong Wan Seo; Sung Koo Lee
Journal:  Gut Liver       Date:  2009-12-31       Impact factor: 4.519

7.  Stereotactic high dose fraction radiation therapy of extracranial tumors using an accelerator. Clinical experience of the first thirty-one patients.

Authors:  H Blomgren; I Lax; I Näslund; R Svanström
Journal:  Acta Oncol       Date:  1995       Impact factor: 4.089

8.  Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma.

Authors:  Regina V Tse; Maria Hawkins; Gina Lockwood; John J Kim; Bernard Cummings; Jennifer Knox; Morris Sherman; Laura A Dawson
Journal:  J Clin Oncol       Date:  2008-01-02       Impact factor: 44.544

9.  Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial.

Authors:  Riccardo Lencioni; Josep M Llovet; Guohong Han; Won Young Tak; Jiamei Yang; Alfredo Guglielmi; Seung Woon Paik; Maria Reig; Do Young Kim; Gar-Yang Chau; Angelo Luca; Luis Ruiz Del Arbol; Marie-Aude Leberre; Woody Niu; Kate Nicholson; Gerold Meinhardt; Jordi Bruix
Journal:  J Hepatol       Date:  2016-01-22       Impact factor: 25.083

10.  Stereotactic Body Radiation Therapy (SBRT) Combined With Chemotherapy for Unresected Pancreatic Adenocarcinoma.

Authors:  Marie K Gurka; Christine Kim; Aiwu Ruth He; Aline Charabaty; Nadim Haddad; Jenna Turocy; Lynt Johnson; Patrick Jackson; Louis M Weiner; John L Marshall; Sean P Collins; Michael J Pishvaian; Keith Unger
Journal:  Am J Clin Oncol       Date:  2017-04       Impact factor: 2.339

View more
  7 in total

1.  Arsenic trioxide and sorafenib combination therapy for human hepatocellular carcinoma functions via up-regulation of TNF-related apoptosis-inducing ligand.

Authors:  Lingyan Wang; Zhihui Min; Xiangdong Wang; Mushuang Hu; Dongli Song; Zhenggang Ren; Yunfeng Cheng; Yanhong Wang
Journal:  Oncol Lett       Date:  2018-06-18       Impact factor: 2.967

2.  Characterization and Prediction of Signal Intensity Changes in Normal Liver Parenchyma on Gadoxetic Acid-enhanced MRI Scans after Liver-directed Radiation Therapy.

Authors:  Anthony D Nehlsen; Kunal K Sindhu; Thomas Wolken; Fahad Khan; Christopher K Kyriakakos; Stephen C Ward; Erin Moshier; Bachir Taouli; Michael Buckstein
Journal:  Radiol Imaging Cancer       Date:  2022-07

Review 3.  Cholangiocarcinoma: a site-specific update on the current state of surgical management and multi-modality therapy.

Authors:  Michael K Turgeon; Shishir K Maithel
Journal:  Chin Clin Oncol       Date:  2019-09-02

Review 4.  Moving forward in the treatment of cholangiocarcinoma.

Authors:  Tommaso M Manzia; Alessandro Parente; Ilaria Lenci; Bruno Sensi; Martina Milana; Carlo Gazia; Alessandro Signorello; Roberta Angelico; Giuseppe Grassi; Giuseppe Tisone; Leonardo Baiocchi
Journal:  World J Gastrointest Oncol       Date:  2021-12-15

5.  Hepatic irradiation persistently eliminates liver resident NK cells.

Authors:  Ryosuke Nakano; Masahiro Ohira; Takuya Yano; Yuki Imaoka; Yuka Tanaka; Hideki Ohdan
Journal:  PLoS One       Date:  2018-06-13       Impact factor: 3.240

6.  Proton beam therapy in apneic oxygenation treatment of an unresectable hepatocellular carcinoma: A case report and review of literature.

Authors:  Yi-Lan Lin
Journal:  World J Hepatol       Date:  2018-10-27

7.  Cyclin-Dependent Kinase Regulatory Subunit 2 Indicated Poor Prognosis and Facilitated Aggressive Phenotype of Hepatocellular Carcinoma.

Authors:  Jie Zhang; Qianqian Song; Jinxia Liu; Lina Lu; Yuqing Xu; Wenjie Zheng
Journal:  Dis Markers       Date:  2019-10-22       Impact factor: 3.434

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.